HHS Medicare/Medicaid fraud "crackdown" targets DME, home health, nursing homes.
This article was originally published in The Gray Sheet
Executive SummaryHHS MEDICARE/MEDICAID FIVE-STATE ANTI-FRAUD/ABUSE INITIATIVE will target the durable medical equipment, home health care and nursing home industries. The two-year project -- termed "Operation Restore Trust" and focused on California, Florida, New York, Texas and Illinois -- is part of a "three-pronged crackdown" on Medicare and Medicaid fraud and abuse announced by the Clinton Administration May 3.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.